The survival models demonstrated satisfactory discriminatory performance, with Harrell's concordance index ranging from approximately 0.80 to 0.87 on held-out test data, indicating their ability to rank patients according to their relative progression risk among patients, while exhibiting distinct dynamics, all three models consistently identified clinical variables that indicated neoadjuvant treatment history, neoplasm cancer status, and tumor recurrence as well as the gene <i>MYH6</i> as important predictor variables for PrCa PFS. This evidence concerns the gene MYH6 and neoplasm.